FDA Confirms GLP-1 RA Safety Review: No Increas...

By HEOR Staff Writer

February 2, 2026

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysi...
Expansion of Generic Medicines Authorization in Portugal
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained
Characterizing Burnout in Health Professionals: Insights from the BEATS Study...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
Accelerating FAST-EU Clinical Trials
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management